Neonatal hyperbilirubinemia is one of the most common conditions managed by pediatricians. Although many infants are affected, most will experience complete resolution without complication. Acute bilirubin encephalopathy and kernicterus are rare yet debilitating sequelae of severe hyperbilirubinemia that can be avoided through careful monitoring and treatment with phototherapy. Appropriate management of neonatal hyperbilirubinemia must balance the risks of these severe conditions with the effects of overtreatment. Released in 2022, the American Academy of Pediatrics revised the clinical practice guideline for the management of hyperbilirubinemia, which aims to provide that balance through updates to the previous guideline. This article will provide the reader with (1) an evidence-based harm and benefit analysis of the guideline, (2) an overview of key changes and clarifications made in the new guideline, and (3) a practical summary of guideline updates. [Pediatr Ann. 2024;53(6):e208-e216.].

中文翻译：

---

新生儿高胆红素血症的管理：揭示美国儿科学会 2022 年临床实践指南修订版。


新生儿高胆红素血症是儿科医生最常见的病症之一。尽管许多婴儿受到影响，但大多数都会完全消退，没有并发症。急性胆红素脑病和核黄疸是严重高胆红素血症的罕见但令人衰弱的后遗症，可以通过仔细监测和光疗治疗来避免。对新生儿高胆红素血症的适当管理必须平衡这些严重疾病的风险与过度治疗的影响。美国儿科学会于 2022 年发布，修订了高胆红素血症管理的临床实践指南，旨在通过更新之前的指南来实现这种平衡。本文将为读者提供（1）基于证据的指南危害和益处分析，（2）新指南中关键变化和澄清的概述，以及（3）指南更新的实用总结。 [小儿安。 2024；53(6):e208-e216。]。